echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Beilu Pharmaceutical Gadopentetate Meglumine Injection Passed the Consistency Evaluation of Generic Drugs

    Beilu Pharmaceutical Gadopentetate Meglumine Injection Passed the Consistency Evaluation of Generic Drugs

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 26, Beilu Pharmaceutical issued an announcement stating that the company had received the "Drug Supplementary Application Approval Notice" for two specifications of Gadopentetate meglumine injection issued by the National Medical Products Administration.


    The company's gadopentetate meglumine injection obtained the National Class II New Drug Certificate issued by the Ministry of Health in 1992; it is mainly used for magnetic resonance imaging of human organs and tissues such as the central nervous system (brain and spinal cord), abdomen, chest, pelvis, limbs, etc.


    According to relevant national policies, appropriate support will be given to medical insurance payment for drug varieties that have passed the consistency evaluation, and medical institutions will give priority to purchase and use in clinical practice


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.